FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria Peptidica

TB-500

Thymosin Beta-4 / TB4 / Tβ4

Recovery & Repair

TB-500 is a synthetic fragment of Thymosin Beta-4 (TB4), a naturally occurring 43-amino acid protein found in virtually all human and animal cells that plays a critical role in tissue repair and regeneration. Originally studied extensively in equine veterinary medicine, it has become one of the most widely researched recovery peptides in clinical and preclinical settings. Its primary applications center on wound healing, reduction of inflammation, and promotion of cellular migration to injury sites.

Meccanismo d'azione

Synthetic analog of thymosin beta-4. Promotes cell migration by sequestering G-actin and upregulating actin polymerization. Reduces inflammation via NF-kB modulation, promotes stem cell differentiation, and accelerates wound healing and tissue repair.

Protocolli di ricerca

Solo per scopi di ricerca. Non è consiglio medico.

Research protocols use 2-5mg twice weekly for the loading phase (4-6 weeks), then 2mg weekly for maintenance. Subcutaneous injection. Some protocols use intramuscular injection near injury site.

Note di ricerca

Clinical Research Status

TB-500 remains investigational with no FDA approval for human use, though Thymosin Beta-4 has been studied in human clinical trials for wound healing and corneal repair. RegeneRx Biopharmaceuticals conducted Phase 2 trials on the full-length TB4 molecule for dermal and ocular indications. The synthetic fragment TB-500 (amino acids 17-23 of TB4) is widely available through research chemical suppliers.

Key Published Findings

Animal studies demonstrate significant acceleration of wound closure, hair regrowth, and cardiac tissue repair following ischemic injury. TB4 upregulates actin polymerization and promotes cellular migration, angiogenesis, and extracellular matrix deposition. Research in rodent models shows reduced scar formation and improved functional recovery from muscle tears and ligament injuries.

Safety Profile

No serious adverse events were reported in human clinical trials of Thymosin Beta-4 at therapeutic doses. Common anecdotal reports include transient head rush, lethargy at initiation, and mild irritation at injection sites. The peptide is banned by WADA under section S2 (Peptide Hormones, Growth Factors, Related Substances).

Drug Interactions & Contraindications

No well-documented drug interactions exist due to limited human clinical data. Theoretical concern exists regarding use in individuals with active cancer, as TB4's pro-angiogenic and cell migration properties could theoretically promote tumor progression. Should be avoided in individuals with known malignancies pending further safety data.

Comparison to Related Compounds

TB-500 is frequently stacked with BPC-157 in recovery protocols, with the two peptides thought to work synergistically through complementary mechanisms (systemic vs. local repair). Unlike BPC-157 which acts primarily through growth factor modulation, TB-500 works via actin sequestration and cytoskeletal reorganization. Full-length Thymosin Beta-4 is more expensive and less stable than the TB-500 fragment.

Community Observations

Most commonly dosed at 2-5mg injected subcutaneously 1-2 times per week during a loading phase, then reduced to weekly maintenance. Users frequently report improved recovery from musculoskeletal injuries within 2-4 weeks of initiation. The peptide is popular among athletes and those recovering from surgical procedures or chronic tendon injuries.

Semplifichro

~6-8 hours

Riconcimimento

Bacteriostatic water (BAC)

Conservazione

Lyofilizzato

Refrigerate 2-8C up to 18 months.

Riconcimato

Refrigerate 2-8C. Use within 14 days.

Stato legale USA

Research chemical (not FDA-approved)

Anche noto come

Thymosin Beta-4TB4Tβ4

Domande frequenti

Che cos'è TB-500?

TB-500 is a synthetic fragment of Thymosin Beta-4 (TB4), a naturally occurring 43-amino acid protein found in virtually all human and animal cells that plays a critical role in tissue repair and regeneration. Originally studied extensively in equine veterinary medicine, it has become one of the most widely researched recovery peptides in clinical and preclinical settings. Its primary applications center on wound healing, reduction of inflammation, and promotion of cellular migration to injury sites.

Come agisce TB-500?

Synthetic analog of thymosin beta-4. Promotes cell migration by sequestering G-actin and upregulating actin polymerization. Reduces inflammation via NF-kB modulation, promotes stem cell differentiation, and accelerates wound healing and tissue repair.

Qual è lo stato normativo di TB-500 negli Stati Uniti?

Research chemical (not FDA-approved)

Qual è l'emivita di TB-500?

~6-8 hours

Con quali altri nomi è noto TB-500?

Thymosin Beta-4, TB4, Tβ4

Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.

Leggi l'intera dichiarazione di responsabilità